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ABSTRACT 
Introduction: osteosarcoma is the most common primary bone tumor in children and young adults and 
appropriate chemotherapy can increase limb sparing and overall survival. Yet, the toxicity of chemotherapy 
regimens including MTX can be life threatening. Therefore; we tried another chemotherapy regimen for these 
patients. 
Method and materials: we investigated 15 patients aged 15 to 40 years old and used continuous infusion of 
cisplatin, doxorubicin intermittently with ifosfamide, doxorubicin as neoadjuvant chemotherapy. Percent of 
necrosis and toxicities was recorded for each patient. 
Results: Out of 15 patients investigated, 13 were males and 2 females. Tumor necrosis≥ 90% (defined as 
good necrosis) was observed in 60% of patients. 26.7% of the patients showed leucopenia grade three or 
four, 26.7% had anemia grade three or four, and 20% showed thrombocytopenia grade three or four. 
Conclusion: The above chemotherapy regimen can cause as good necrosis as the chemotherapy regimens 
including high dose of MTX with reduced toxicity and less nursing cares and laboratory tests. Of course small 
sample size limits extension of our result to all patients but trying this regimen is recommended in more 
patients to see more reliable results.  
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INTRODUCTION 
   Osteosarcoma is the most common primary 
malignant bone tumor in children and young 
adults.1,2 Although in the past it was a lethal 
disease, achieving chemotherapy in last 30 years 
has raised the 5-year survival of these patients to 75 
%.3 On the other hand using chemotherapy before 
surgery gives us the opportunity of saving the limb 
in these patients.4,5 So chemotherapy is now 
accepted as the standard preoperative option. But 
the type of chemotherapy is yet in controversy with 
the majority of regimens, including doxorubicin and 
cisplatin, with or without high-dose methotrexate 
(HDMTX, 6 to 12 g/m2 with leucovorin 
rescue).6,7,8,9,10 Although methotrexate is used in 
many centers in combination with cisplatin and 
doxorubicin as an standard neoadjuvant and 
adjuvant chemotherapy, its toxicity and nursing 
care required for exact dose and time of calcium 
folinate injection has become an important concern 
for using MTX in centers not specialized for treating 
such patients. So we tried ifosfamide instead of 
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MTX and investigated for the necrosis percent and 
side effects of this chemotherapy regimen. On the 
other hand we used 24 hour infusion of cisplatin to 
increase its effect and reduce toxicity. 
 
MATERIALS AND METHODS 
   15 patients with non-metastatic osteosarcoma, 
who referred to our center for neoadjuvant 
chemotherapy since September 2005 to October 
2009, were recruited into our study. The range of 
patients, age was between 17 to 40 years old. The 
osteosarcoma was diagnosed by bone biopsy. 
Before chemotherapy function of liver and kidney 
were checked as well as hematologic profile. 
Imaging was done for ruling out metastasis. If there 
was no metastasis or contraindication for 
chemotherapy, regarding to laboratory tests, the 
following chemotherapy began for 4 cycles 
intermittently. After 4 courses done definitive 
surgery was done and percent of necrosis 
determined by a single pathologist. The side effects 
of chemotherapy were recorded. Chemotherapy 
regimen was doxorubicin and ifosfamide. 
Doxorubicin 75 mg/m2 administered as one hour 
continuous infusion. IFO, in combination with an 
equimolar dose of mesna (800 mg three times a 
day), was administered as a continuous intravenous 
infusion (8 g/m2) as a 120-hour continuous infusion, 
intermittent with of doxorubicin and cisplatin. 
Cisplatin was infused during 24 hours as a 
continuous intravenous infusion (100 mg/m2) in 
combination with doxorubicin (70 mg/m2) in one-
hour infusion in three consequent days. 
Granulocyte colony-stimulating factor was 
administered after each cycle for 5 days. 9 to 15 
weeks after the last cycle of chemotherapy surgery 
was done. The histological response to primary 
treatment was assessed in terms of persistence of 
viable tumor cells or absence of viable tumor cells 
(total necrosis). 
 
RESULTS 
   Age of patients was between 15 to 40 years old, 
13 males and 2 females. The mean age was 20.1 ± 
6.6 years. Tumor necrosis ≥ 90% (defined as good 
necrosis) was observed in 60% of patients. The 
mean percent of tumor necrosis was 75.5% ± 
31.5%. 69.2% of male patients have good pathologic 
response (over 90%) and 30.8% of them have poor 
pathologic response in comparison to female 
patients who all showed poor pathologic response. 
Table1 shows the frequency of each pathologic 
necrosis grade in patients according to the grading 
system presented by Huvos et al. By this regard, 
60% 0f patients have 90% or more necrosis in their 
pathologic samples.  
 
Table 1: The Frequency of each Pathologic Grade in Patients 
with Osteosarcoma after Neoadjuvant Chemotherapy 
Grade Number of patients (percent) 
Grade I without necrosis 2 (13.3%) 
Grade II (50% - 89% necrosis) 4 (26.7%) 
Grade III (90% ≤ necrosis < 
100) 
7 (46.7%) 
Grade IV (100% necrosis) 2 (13.3%) 
 
The mean age of patients with good pathologic 
response was 21.2 ± 7.8 and the mean age of 
patients with poor pathologic response was 18.5 ± 
4.4 years. 3 patients were hospitalized because of 
the side effects of neoadjuvant chemotherapy. 
26.7% of patients showed leucopenia in grade three 
or four, 26.7% had anemia grade three or four, and 
20% thrombocytopenia grade three or four. 
Mocositis was another side effect of neoadjuvant 
chemotherapy. Other side effects included: 
hemorrhagic cystitis in 3 patients, chest pain with T 
inversion in pericardial electrocardiographic leads in 
one patient (with normal ejection fraction and 
cardiac enzymes), and hypokalemia in 2 patients. All 
these side effects were treated properly without 
any secondary sequel. There was not any evidence 
of nephrotoxicity, neurotoxicity, or ototoxicity in 
any cases. 
 
DISCUSSION 
   Ferrari S reported 45 % good necrosis in patients 
treated with drugs (ADM 420 mg/m2, MTX 120 
g/m2, CDP 600 mg/m2 and IFO 30 g/m2)11 but in our 
patients good necrosis occurred in 60% of cases .In 
the Ferrari study there was 4 dead due to toxicity 
but none of our patients died of chemotherapy 
.Daw NC in his study reported 60%good necrosis in 
patient treated with carboplatin, ifosfamide, 
doxorubicin that is comparable with our study and 
it is another document for good necrosis without 
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MTX and even cisplatin.12 In systemic review done 
by van Dalen EC there have not been any strong 
evidences for use of high dose MTX in 
osteosarcoma and he didn’t recommend MTX use in 
ordinary chemotherapy for patients with 
osteosarcoma.13 Besides high dose MTX increase 
hospitalization and cause serious side effects in 
patients with excretion.14, 15 So high dose MTX 
prescription needs measuring its level and 
hydration and urine alkalization with laboratory 
measurements.14,15,16 In our study good necrosis 
was less in female but in Collins M study good 
necrosis was more in females,17 although our small 
sample size is a limitation for final conclusion. 
Kudawara I also showed 66% of good necrosis with 
chemotherapy regimen including high dose MTX.18 
It is close to our result, But in our study there was 
not any need for frequent laboratory tests. So use 
of the above mentioned regimen with lower and 
predictable toxicity and less laboratory tests can be 
substituted for high dose MTX with the same 
percent of good necrosis, but we must consider the 
sample size for interpreting the final results and our 
small sample size is limitation of our study.  
   Considering the results of our study, which 
revealed less side effects and good necrosis with 
the new chemotherapy regimen, we suggest that 
more studies with bigger sample size needs to be 
done to confirm the new regimen as standard 
adjuvant chemotherapy for osteosarcoma. 
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